23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
23andMe (Nasdaq: ME) announced positive preliminary Phase 2 safety and efficacy data for 23ME-00610, a first-in-class anti-CD200R1 antibody, at the ESMO Congress 2024. Key findings include:
1. A confirmed partial response in a patient with refractory clear-cell renal-cell carcinoma (ccRCC).
2. Acceptable safety and tolerability profile.
3. Higher tumor expression of CD200 may be associated with clinical benefit.
4. Potential effectiveness in 'cold' tumors, suggesting opportunity for patients unable to benefit from PD-1/PD-L1 checkpoint inhibitors.
The study included 10 ccRCC patients and 13 patients with TMB-H or MSI-H cancers. The data suggests that interrupting the CD200/CD200R1 pathway has potential to reverse immune suppression in the tumor microenvironment.
23andMe (Nasdaq: ME) ha annunciato dati preliminari positivi di sicurezza ed efficacia della Fase 2 per 23ME-00610, un anticorpore anti-CD200R1 di prima classe, al Congresso ESMO 2024. I risultati chiave includono:
1. Una risposta parziale confermata in un paziente con carcinoma renale a cellule chiare refrattario (ccRCC).
2. Un profilo di sicurezza e tollerabilità accettabile.
3. Un'alta espressione tumorale di CD200 potrebbe essere associata a benefici clinici.
4. Potenziale efficacia nei tumori 'freddi', suggerendo un'opportunità per i pazienti che non riescono a beneficiare dagli inibitori del checkpoint PD-1/PD-L1.
Lo studio ha incluso 10 pazienti con ccRCC e 13 pazienti con tumori TMB-H o MSI-H. I dati suggeriscono che interrompere il percorso CD200/CD200R1 ha il potenziale di invertire la soppressione immunitaria nel microambiente tumorale.
23andMe (Nasdaq: ME) anunció datos preliminares positivos de seguridad y eficacia de la Fase 2 para 23ME-00610, un anticuerpo anti-CD200R1 de primera clase, en el Congreso ESMO 2024. Los hallazgos clave incluyen:
1. Una respuesta parcial confirmada en un paciente con carcinoma de células renales de tipo claro refractario (ccRCC).
2. Un perfil de seguridad y tolerabilidad aceptable.
3. Una mayor expresión tumoral de CD200 puede estar asociada con un beneficio clínico.
4. Potencial efectividad en tumores 'fríos', sugiriendo una oportunidad para pacientes que no pueden beneficiarse de los inhibidores de punto de control PD-1/PD-L1.
El estudio incluyó 10 pacientes con ccRCC y 13 pacientes con cánceres TMB-H o MSI-H. Los datos sugieren que interrumpir la vía CD200/CD200R1 tiene potencial para revertir la supresión inmunitaria en el microentorno tumoral.
23andMe (Nasdaq: ME)는 ESMO 회의 2024에서 첫 번째 항-CD200R1 항체인 23ME-00610에 대한 2상 안전성 및 효능에 대한 긍정적인 초기 데이터를 발표했습니다. 주요 결과는 다음과 같습니다:
1. 치료에 저항하는 투명세포 신장세포 암(cancer) 환자에서 확인된 부분 반응.
2. 수용 가능한 안전성 및 내약성 프로필.
3. CD200의 높은 종양 발현이 임상 이점과 연관될 수 있음.
4. '차가운' 종양에 대한 잠재적 효과, PD-1/PD-L1 체크포인트 억제제의 혜택을 받을 수 없는 환자에게 기회가 있음을 시사합니다.
이 연구에는 10명의 ccRCC 환자와 13명의 TMB-H 또는 MSI-H 암 환자가 포함되었습니다. 데이터는 CD200/CD200R1 경로를 차단하는 것이 종양 미세환경에서 면역 억제를 역전시킬 잠재력이 있음을 제안합니다.
23andMe (Nasdaq: ME) a annoncé des données préliminaires positives de sécurité et d'efficacité de la phase 2 pour 23ME-00610, un anticorps anti-CD200R1 de première classe, lors du Congrès ESMO 2024. Les résultats clés comprennent :
1. Une réponse partielle confirmée chez un patient atteint de carcinome rénal à cellules claires réfractaire (ccRCC).
2. Un profil de sécurité et de tolérance acceptable.
3. Une expression tumorale élevée de CD200 pourrait être associée à un bénéfice clinique.
4. Efficacité potentielle dans les tumeurs 'froides', suggérant une opportunité pour les patients ne pouvant bénéficier des inhibiteurs de point de contrôle PD-1/PD-L1.
Cette étude a inclus 10 patients atteints de ccRCC et 13 patients présentant des cancers TMB-H ou MSI-H. Les données suggèrent qu'interrompre la voie CD200/CD200R1 pourrait avoir le potentiel d'inverser la suppression immunitaire dans le microenvironnement tumoral.
23andMe (Nasdaq: ME) gab positive vorläufige Daten über Sicherheit und Wirksamkeit der Phase 2 für 23ME-00610, einen erstmaligen anti-CD200R1-Antikörper, auf dem ESMO-Kongress 2024 bekannt. Zu den wichtigsten Ergebnissen gehören:
1. Eine bestätigte partielle Ansprechrate bei einem Patienten mit refraktärem klarzelligem Nierenzellkarzinom (ccRCC).
2. Ein akzeptables Sicherheits- und Verträglichkeitsprofil.
3. Eine höhere tumorale Expression von CD200 könnte mit klinischen Vorteilen verbunden sein.
4. Potenzielle Wirksamkeit bei 'kalten' Tumoren, was eine Chance für Patienten suggeriert, die nicht von PD-1/PD-L1-Checkpoint-Inhibitoren profitieren können.
Die Studie umfasste 10 Patienten mit ccRCC und 13 Patienten mit TMB-H- oder MSI-H-Krebs. Die Daten deuten darauf hin, dass die Unterbrechung des CD200/CD200R1-Signalwegs das Immunsuppressionspotenzial im Tumormikroumfeld umkehren könnte.
- Confirmed partial response (38% decrease in tumor burden) in a refractory ccRCC patient
- Acceptable safety and tolerability profile of 23ME-00610
- Higher tumor expression of CD200 associated with clinical benefit in some patient groups
- Potential effectiveness in 'cold' tumors, expanding treatment options
- Evidence of immune modulation with 23ME-00610 treatment
- Small sample size (10 ccRCC patients, 13 TMB-H/MSI-H patients) limits conclusiveness of results
- Only one confirmed partial response reported in ccRCC cohort
- Majority of patients discontinued treatment, with only 3 ccRCC and 1 TMB-H/MSI-H patient remaining on study at data cutoff
The Phase 2 results for 23ME-00610 show promising early efficacy in clear-cell renal-cell carcinoma (ccRCC) and TMB-H/MSI-H cancers. The confirmed partial response in a ccRCC patient is particularly noteworthy, given the heavily pretreated population. The drug's acceptable safety profile is encouraging for potential combination therapies.
The correlation between higher CD200 expression and clinical benefit suggests a potential biomarker for patient selection, which could improve treatment outcomes. The observation that '610 may be more effective in "cold" tumors is intriguing, as it could address an unmet need for patients who don't respond to current immunotherapies.
However, the small sample sizes (10 ccRCC, 13 TMB-H/MSI-H patients) limit the strength of these conclusions. Larger studies will be needed to confirm these findings and establish '610's efficacy across different cancer types.
The development of 23ME-00610 represents a novel approach in immuno-oncology by targeting the CD200/CD200R1 pathway. Its potential efficacy in "cold" tumors is particularly exciting, as these patients often have treatment options after progressing on existing checkpoint inhibitors.
The 38% tumor reduction in a refractory ccRCC patient is encouraging, especially considering the median of four prior treatment lines in this cohort. The drug's ability to potentially reverse immunosuppression in the tumor microenvironment could be a game-changer if confirmed in larger studies.
The emerging biomarker data, combining CD200 expression with host genetics, is a sophisticated approach that could lead to more personalized treatment strategies. However, it's important to validate these biomarkers in larger, prospective studies before clinical implementation.
These results are positive for 23andMe's therapeutics pipeline, demonstrating the potential of their genetics-driven drug discovery approach. The company's unique position in combining genetic data with drug development could provide a competitive advantage in the crowded immuno-oncology space.
The potential for a predictive biomarker based on CD200 expression and genetic factors could significantly de-risk future clinical trials and improve the drug's commercial prospects if approved. This aligns with the industry trend towards precision medicine and could attract partnership interest from larger pharma companies.
However, investors should note that 23ME-00610 is still in early-stage development. While promising, these results need to be replicated in larger, randomized trials. The company's ability to fund continued development and potentially bring this asset to market will be important for long-term value creation.
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response
Higher tumor expression of CD200 and human genetics correlated with increased clinical benefit, suggesting potential value as patient selection biomarkers
Greater response in “cold” tumors suggests opportunity in patients unable to benefit from PD-1/PD-L1 checkpoint inhibitors
SUNNYVALE, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from its Phase 1/2a clinical trial covering two new patient cohorts from 23ME-00610 (’610), a first-in-class anti-CD200R1 antibody, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, September 13-17.
23andMe Therapeutics presented posters summarizing results for 10 patients with clear-cell renal-cell carcinoma (ccRCC) and for 13 patients with tumor mutational burden-high (TMB-H) or microsatellite instability-high (MSI-H) cancers. A third poster summarized data from 118 participants across the Phase 1/2a trial to evaluate high tumor expression of CD200 as a potential predictive biomarker of clinical benefit. These presentations supplement data for cohorts with neuroendocrine and ovarian cancer presented earlier this year at the 2024 American Society of Clinical Oncology Meeting. (The 23andMe ESMO posters are available on the 23andMe Therapeutics and Investor websites).
“We continue to be encouraged by evidence for therapeutic potential, in the form of multiple patients with durable clinical benefit from ’610,” said Jennifer Low, M.D., Ph.D., Head of Therapeutics Development, 23andMe. “Furthermore, the emergence of CD200 expression as a candidate biomarker has the potential to give us a powerful tool for patient selection. The progress we have made to date suggests that interrupting the CD200/CD200R1 pathway has great potential to reverse immune suppression in the tumor microenvironment and to help cancer patients who have progressed after multiple lines of treatment, including existing checkpoint inhibitors.”
23ME-00610 is a first-in-class IgG1 antibody designed to reverse immunosuppression by inhibiting binding of CD200R1 on immune cells with CD200 on tumor cells. In preclinical studies, this mechanism leads to restoration of T cell activity and killing of CD200-expressing tumor cells. The CD200R1 axis was recognized as a potentially significant checkpoint inhibition pathway through the identification of pleiotropic causal variants with opposing effect on risk for cancer and immune diseases, referred to by 23andMe Therapeutics as an immuno-oncology signature.
Key Takeaways:
- Confirmed partial response (
38% decrease in measured tumor burden) in a patient with refractory ccRCC (>11 cycles at data cut-off). - 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed every three weeks.
- Higher tumor expression of CD200 may be associated with clinical benefit in some patient groups treated with 23ME-00610, warranting further exploration of this biomarker.
- In addition to CD200 expression, histology data suggest that immunosuppressed (“cold”) tumors may be more likely to exhibit disease control with 23ME-00610. Biopsied patients that had tumor shrinkage or prolonged stable disease with 23ME-00610 treatment tended to be less inflamed at baseline and have lower levels of immunosuppressive (M2) macrophages.
- Emerging data demonstrate the potential interaction of a tumor biomarker with host genetics, leveraging 23andMe developed polygenic risk scores.
Further details - ccRCC cohort
- Between June 5 and December 12, 2023, ten adult patients with advanced ccRCC who received a median of four prior treatment lines (range: 2-7) were enrolled and received a median of three cycles (range: 2-12) of 23ME-00610, with three patients remaining on study at the July 1, 2024 data cutoff.
- In a 61 year old male, a confirmed partial response and ongoing treatment duration > 32 weeks for a treatment of refractory kidney cancer with high CD200 tumor expression was observed.
- The safety and tolerability profile remains acceptable and promising for potential anti-cancer combinations in ccRCC patients.
- No treatment-emergent adverse events (TEAEs) leading to 23ME-00610 dose interruption or discontinuation were reported.
- Related treatment-emergent adverse events (TEAEs) occurred in three patients (
30% ); all were G1/G2, were reported once each (10% ), and included dry mouth, nausea, constipation and vomiting.
- Preliminary baseline tumor data may suggest that highly vascularized tumors with high CD200 associates with benefit from 23ME-00610 treatment.
Further details – TMB-H/MSI-H cohort
- Between June 20, 2023 and April, 2024, 13 adult patients with locally advanced or metastatic TMB-H (N=11;
84.6% ) and/or MSI-H (N=5;38.5% ) solid cancers who received a median of five prior treatments (range 3-11; prior immunotherapy in84.6% ) were enrolled and received a median of three cycles of 23ME-00610 (range 1-11), and 1 patient remaining on study at the July 1, 2024 data cutoff.
Further details – CD200 biomarker
- Between January 2022 and April 2024, 118 adult patients with locally advanced and metastatic solid tumors were enrolled in the Phase 1/2a clinical trial for 23ME-00610. Archival tissue and genotyping was requested from all patients, and some subsets of patients received baseline and on-treatment biopsies.
- Higher tumor cell expression of CD200 associates with 23ME-00610 in some patients, and is further augmented if combined with genetic based host immune set point readouts (e.g. autoimmune hypothyroidism polygenic risk score), warranting further exploration of this and other biomarkers for potential future patient selection.
- Neuroendocrine tumors that had tumor shrinkage or prolonged stable disease tended to be less inflamed at baseline, though potentially more permissive to immune activation due to lower macrophage to lymphocyte ratio.
- Analysis of pre- and on-treatment tumor samples showed an increase in T and NK cell markers and an increase in interferon inducible genes with 23ME-00610 treatment suggesting pharmacodynamic immune modulation.
About 23ME-00610
23ME-00610 is a monoclonal antibody that binds to CD200R1 to prevent the interaction of CD200R1 with CD200. Using the world’s largest proprietary database of health and genetic information, 23andMe identified genetic variants of CD200R1, CD200, and DOK2, the downstream signaling protein, associated with higher risks of immune disease and lower risks of cancer, pinpointing CD200R1 as a promising immuno-oncology target.
Additional preclinical data validated the CD200-CD200R1 pathway as an immune checkpoint, and potential target for reversing immune tolerance in cancer as a monotherapy, or in combination with other therapies. Clinical data from the dose escalation cohort of patients with advanced solid tumors has shown 23ME-00610 has favorable pharmacokinetics (PK) for dosing once every three weeks, expected on-target pharmacologic activity, and a promising safety and tolerability profile.
About 23andMe
23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visit https://therapeutics.23andme.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
Contacts:
Investor Relations Contact: investors@23andMe.com
Media Contact: press@23andMe.com
FAQ
What are the key results of 23andMe's Phase 2 trial for 23ME-00610 in cancer treatment?
How does 23ME-00610 work in cancer treatment?
What potential biomarkers for 23ME-00610 efficacy were identified in the study?
What types of cancer patients were included in the 23andMe (ME) Phase 2 trial for 23ME-00610?
